Shots:
- mAbxience, majority-owned by Fresenius Kabi and partially by Insud Pharma, has partnered with Abiogen Pharma in a strategic licensing agreement to develop & commercialize a biosimilar in Italy
- As per the agreement, mAbxience will hold marketing authorization, while Abiogen Pharma handles commercialization and marketing in Italy
- This collaboration leverages mAbxience’s biosimilar development expertise and Abiogen Pharma’s robust commercial footprint in the Italian market.
Ref: mAbxience & Abiogen Pharma | Image: mAbxience & Abiogen Pharma| Press Release
Related News:- Roche’s Itovebi Regimen Secures the CHMP’s Positive Opinion for PIK3CA-mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
